Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05785832 · ClinicalTrials.gov registry record · NA
A Randomized Trial Evaluating Control-IQ+ Technology in Adults With Type 2 Diabetes
A NA study, sponsored by Tandem Diabetes Care.
- Completed
- Registry status
- NA
- Development phase
- 319
- Enrollment target
NCT05785832: Completed NA study, sponsored by Tandem Diabetes Care.
NCT05785832 is a NA study that has completed, run by Tandem Diabetes Care. The registered enrollment target is 319 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05785832, a NA study, has completed, sponsored by Tandem Diabetes Care.
- COMPLETED
- Registry status
- NA
- Development phase
- 319 participants
- Enrollment target
Study Summary
A randomized controlled trial (RCT) to assess the safety and efficacy of use of Control-IQ+ technology in adults with type 2 diabetes using basal-bolus insulin therapy.
Primary Outcome
Change in HbA1c (%) from baseline between the intervention and control groups
Interventions
- DEVICE t:slim X2 insulin pump with Control-IQ+ technology and Dexcom G6 CGM
- DEVICE Standard Therapy plus continuous glucose monitoring (CGM)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 319 participants |
| Start Date | 2023-06-01 |
| Est. Completion | 2024-09-24 |
| Phase | NA |
What the finished NCT05785832 record still lists
NCT05785832 is an interventional study that assigns participants to a tested intervention. The registered 319 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (77% lower).
The record links to 0 conditions, and to 2 interventions - of which t:slim X2 insulin pump with Control-IQ+ technology and Dexcom G6 CGM is the first listed.
NCT05785832 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05785832 about?
NCT05785832 is a clinical study titled "A Randomized Trial Evaluating Control-IQ+ Technology in Adults With Type 2 Diabetes". A randomized controlled trial (RCT) to assess the safety and efficacy of use of Control-IQ+ technology in adults with type 2 diabetes using basal-bolus insulin therapy.
What is the current status of trial NCT05785832?
This trial is currently completed. It is a NA study. The enrollment target is 319 participants. The study started on 2023-06-01. Estimated completion is 2024-09-24.
What interventions are being tested in trial NCT05785832?
The interventions under investigation include: t:slim X2 insulin pump with Control-IQ+ technology and Dexcom G6 CGM (DEVICE), Standard Therapy plus continuous glucose monitoring (CGM) (DEVICE).
Who is sponsoring clinical trial NCT05785832?
This trial is sponsored by Tandem Diabetes Care, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05785832's enrollment target sits among peer trials
319 321st of 2000 higher than 1,680 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05377996 · 319 participants · Phase 1
A Study of XMT-1660 in Participants With Solid Tumors
- NCT02763683 · 320 participants
Investigations of Dementia in Parkinson Disease
- NCT03331198 · 320 participants · Phase 1
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
- NCT03458832 · 320 participants
Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI